Editor's Letter

Published on 10 August 2025

A spectrum of generics and biosimilars: research, reports, and interviews

In this second issue of 2025, we have a diverse spectrum of publications which include one original research paper in the generics area and biosimilar-focused articles which comprise one special report, one meeting report, one interview and one sponsored article.  The first article in this issue is an Original Research paper titled ‘Therapeutic equivalence of…

Author(s): Robin Thorpe, PhD, FRCPath

DOI: 10.5639/gabij.2025.1402.006

---

Table Contents

Published on 15 April 2024

2024/1 GaBI Journal Table of Contents

Editor’s Letter First 2024 GaBI Journal issue highlights Original Research Budget impact analysis of a rituximab intravenous biosimilar in patients with follicular lymphoma and large B-cell non-Hodgkin lymphoma in Chile Pharmacokinetic bioequivalence studies of a new Etoricoxib tablet formulation developed using proprietary MiST technology — risk assessment and mitigation using GastroPlus software Perspective Comparative efficacy…

---

Editor's Letter

Published on 15 December 2025

New research in biosimilars: oncology barriers, PFS handling, and Australian policy

In this third issue of 2025, we have pub- lications which include two editorials and three original research papers. All are in the biosimilars area and once more we have no papers dealing with generics. We strongly encourage potential authors of manuscripts in the generics field as well as those on biosimilars to submit them…

Author(s): Robin Thorpe, PhD, FRCPath

DOI: 10.5639/gabij.2025.1403.012

---

Original Research

Published on 23 March 2026

Real-world evaluation of dosing and haemoglobin A1c (HbA1c) in patients converted from insulin glargine (Lantus®) to insulin glargine (Basaglar®) in Saudi Arabia 

Introduction/Study objective: About 28% of Saudi Arabia population above 15 years old are diagnosed with diabetes. Basal insulin glargine Lantus and its’ biosimilar Basaglar, are long-acting insulin that regulate blood glucose levels over 24 hours. Patients switch between basal insulins for various reasons including adverse events, availability and cost. Switching should be done with careful…

Author(s): Salwa Almomen, MD, MSc, Fares Alrubaish, PharmD, Radwan Hafiz, PharmD, Ali M Alhomaidan, PhD

biosimilars, HbA1c, interchangeability, long-acting insulin analogues, switching, treatment conversion

DOI: 10.5639/gabij.2026.1501.

---